Filing Details

Accession Number:
0001179110-17-003204
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-02-24 18:35:21
Reporting Period:
2017-02-22
Filing Date:
2017-02-24
Accepted Time:
2017-02-24 18:35:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1235010 Momenta Pharmaceuticals Inc MNTA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1229450 A Craig Wheeler C/O Momenta Pharmaceuticals, Inc.
675 West Kendall Street
Cambridge MA 02142
President Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2017-02-22 1,688 $15.51 305,303 No 4 S Direct
Common Stock Disposition 2017-02-22 1,969 $15.51 303,334 No 4 S Direct
Common Stock Disposition 2017-02-22 1,969 $15.51 301,365 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 261,941 Indirect Craig Wheeler Revocable Trust
Footnotes
  1. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2013.
  2. This transaction was executed in multiple trades at prices ranging from $15.30 to $15.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 12, 2014.
  4. This transaction was executed in multiple trades at prices ranging from $15.30 to $15.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  5. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2015.